Vaxart, Inc.

VXRT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-9.6M $-25.4M $-19.1M $-11.0M $-8.9M $-19.2M $-4.5M $878.0K
Depreciation & Amortization $380.0K $100.0K $1.1M $2.4M $3.0M $3.1M $237.0K $376.0K
Depreciation $376.0K — — — $1.8M $1.8M $1.7M —
Amortization $4.0K — — — — — — —
Stock-Based Compensation $477.0K $2.0M $2.1M $1.7M $2.6M $500.0K $2.2M $3.9M
Net Cash from Operating Activities $-10.0M $-14.1M $-9.6M $-3.3M $-13.9M $-15.9M $-15.2M $39.9M
Investing Activities
Capital Expenditures $117.0K $200.0K $100.0K $100.0K $1.0M $1.3M $1.0K $154.0K
Business Acquisitions — — $8.9M — — — — —
Net Cash from Investing Activities $3.2M — $-19.4M $-10.1M $31.7M $-1.3M $55.2M $2.3M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — $400.0K $700.0K $42.8M
Net Cash from Financing Activities $24.0K — $-100.0K $26.8M — $-400.0K $663.0K $-48.2M
Net Change in Cash $-6.8M $5.0M $-29.1M $13.4M $17.8M $-17.6M $40.7M $-5.9M
Free Cash Flow $-10.2M $-14.3M $-9.7M $-3.4M $-14.9M $-17.2M $-15.2M $39.8M
← Newer Page 2 of 3 Older →